Cargando…
Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial
Hereditary hemorrhagic telangiectasia is a rare vascular genetic disease. Epistaxis is the most frequent and disabling manifestation, and timolol appears to be a new therapeutic option as non-selective beta-blockers have in vitro and in vivo anti-angiogenic properties. Our main objective was to eval...
Autores principales: | Dupuis-Girod, Sophie, Pitiot, Vincent, Bergerot, Cyrille, Fargeton, Anne-Emmanuelle, Beaudoin, Marjolaine, Decullier, Evelyne, Bréant, Valentine, Colombet, Bettina, Philouze, Pierre, Faure, Frédéric, Letievant, Jean-Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700077/ https://www.ncbi.nlm.nih.gov/pubmed/31427745 http://dx.doi.org/10.1038/s41598-019-48502-9 |
Ejemplares similares
-
Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial
por: Dupuis-Girod, Sophie, et al.
Publicado: (2020) -
Obstetrical and neonatal complications in hereditary haemorrhagic telangiectasia: A retrospective study
por: Delagrange, Laura, et al.
Publicado: (2022) -
TIMolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (TIM-HHT)—A Prospective, Randomized, Double-Blind, Controlled, Cross-Over Trial
por: Andorfer, Kornelia E. C., et al.
Publicado: (2022) -
Classifying Ectopia Lentis in Marfan Syndrome into Five Grades of Increasing Severity
por: Zech, Jean-Christophe, et al.
Publicado: (2020) -
Hereditary haemorrhagic telangiectasia and pregnancy: a review of the literature
por: Dupuis, Olivier, et al.
Publicado: (2020)